

# A National Cancer Clinical Trials System for the 21<sup>st</sup> Century:

## Reinvigorating the NCI Cooperative Group Program



INSTITUTE OF MEDICINE

OF THE NATIONAL ACADEMIES

Advising the nation / Improving health

## Some Key Messages

1. Clinical trials make tremendous contributions to improving cancer care. It is imperative that the processes for designing, opening and completing clinical trials become more efficient and streamlined, with more rigorous prioritization.
2. All stakeholders share the goal of improving patient care. They include clinical investigators, pharma/biotech, government funding and regulatory agencies, patients and their advocates, and health care payors, and each looks at the shared goal through different lenses. They all need to participate and collaborate in implementing these recommendations.

## Some Key Messages

3. Clinical trials should place increasing emphasis on innovative design and the use of biomarkers (lab tests and imaging) to target therapy for individual patients (personalized treatment).
4. The FDA needs to balance benefits and risks for patients with advanced cancer, leading to earlier targeted approvals with rigorous post-marketing surveillance.
5. The value of designing and carrying out clinical trials must be recognized by adequate reimbursement of costs. And the non-experimental costs of care for patients on clinical trials should be paid for by insurance.

# To read the report online:

## [www.nap.edu](http://www.nap.edu)

